Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
7,184 total articles
Incannex Healthcare has entered a partnership with the American Academy of Sleep Medicine Foundation to sponsor research in sleep apnea, reflecting its commitment to the field as it advances its lead investigational oral combination therapy, IHL-42X. The company recently achieved strong Phase 2 clinical results and received FDA Fast Track designati…
authID announced a strategic OEM partnership with a disruptive digital identity and continuous background screening tech company to embed its biometric identity verification and authentication technology into the partner's platform. This collaboration aims to provide organizations with reusable digital identity credentials that enable secure onboar…
LB Pharmaceuticals has commenced its pivotal Phase 3 NOVA-2 trial to evaluate LB-102, a novel oral benzamide antipsychotic candidate, for the treatment of schizophrenia in approximately 460 U.S. patients. LB-102 showed promising Phase 2 results with significant symptom improvement and a favorable safety profile. Topline data from NOVA-2 are expecte…
Getty Realty Corp., a US-based net lease REIT focused on convenience and automotive retail real estate, will release its Q1 2026 financial results on April 22, 2026, and host a concurrent earnings call on April 23, 2026. The company's portfolio comprises 1,174 properties across 44 states and Washington, D.C.
zSpace, Inc. highlights a successful partnership with Atlanta Public Schools, demonstrating the transformative power of its AR/VR learning platform in enhancing STEM education and career readiness across multiple school levels over nearly ten years. The immersive technology facilitates hands-on learning experiences that prepare students for workfor…
BullFrog AI Holdings has introduced bfARENAS™, a new AI-powered decision engine designed to support pharmaceutical and biotech companies in optimizing portfolio strategies and clinical trial designs. The tool evaluates options under multiple strategic scenarios, aiming to reduce risk and improve R&D decision-making efficiency amid clinical trial un…
Kestra Medical Technologies, a wearable medical device and digital healthcare firm, has been named a finalist in the 'Deal of the Year' category at the 2026 GeekWire Awards. The nomination recognizes Kestra's impactful 2025 initial public offering, which bolstered the company’s capacity to expand commercially and innovate its Cardiac Recovery Syste…
Kaltura has obtained ISO/IEC 42001 certification, the global standard for Artificial Intelligence Management Systems, recognizing its ability to manage AI-related risks including security and operational misuse. This certification enhances trust in Kaltura’s AI offerings, especially for customers in regulated sectors like financial services, health…
Recursion, a clinical-stage TechBio company, announced that Dr. Vicki Goodman will become Chief Medical Officer on April 6, 2026, succeeding Dr. David Mauro. Dr. Goodman brings extensive oncology drug development expertise from roles at biotech and major pharma companies, enhancing Recursion's leadership as it advances its clinical pipeline and pre…
BIO-key International, a leader in biometric authentication and identity access management solutions, announces its 2025 year-end earnings call scheduled for March 31st. The company will release financial results prior to the market opening, with senior executives hosting the conference call and Q&A session.
Artelo Biosciences announced a fully funded clinical study expanding its lead compound ART27.13 into the $16.3 billion glaucoma market, complementing its existing pipeline targeting oncology support, neuropathic pain, and CNS disorders. The company highlights positive interim Phase 2 data, European patent protection through 2041, supportive regulat…
EDAP TMS S.A. announced record fourth quarter and full-year 2025 revenue growth in its High-Intensity Focused Ultrasound (HIFU) business, with a 39% year-over-year increase driven by stronger global demand for the Focal One system. The company reported increased system sales, notably 14 cash sales in Q4, and 28% growth in U.S. Focal One procedures.…
Anavex Life Sciences has withdrawn its application for European marketing authorization of blarcamesine as an add-on treatment for early Alzheimer's disease after the EMA's Committee for Medicinal Products for Human Use indicated it would not issue a positive opinion at this time. The company plans to gather additional data and conduct further anal…
Creative Realities, Inc. (NASDAQ: CREX), a leading provider of digital signage and AdTech solutions, has appointed Jackie Walker as Chief Experience Officer. With over 15 years’ experience in digital transformation and expertise in retail media networks and QSR digital merchandising, Walker will lead the company’s transition into a software-first p…
Rekor Systems, a NASDAQ-listed leader in roadway intelligence systems, announced the appointment of Marc Segal as Technical Account Management Director for its Rekor Command® real-time traffic operations platform. Based in Austin, Texas, Segal's role aims to accelerate adoption and expand the platform’s presence, leveraging his expertise and existi…
Vera Therapeutics, a Nasdaq-listed biotechnology firm focused on immunological diseases, announced the appointment of Jane Wright-Mitchell as Chief Legal Officer. Wright-Mitchell brings extensive experience in legal, compliance, and regulatory affairs within life sciences, positioning the company to support key milestones and the anticipated commer…
Cipher Digital announces execution of a 15-year lease agreement for a new high-performance computing (HPC) data center campus with an investment-grade hyperscale tenant. The company also closed its first syndicated revolving credit facility of up to $200 million, enhancing liquidity and supporting growth initiatives. This strategic development rein…
HBT Financial, Inc. announced the appointment of Michael J. Morton to its Board of Directors effective April 1, 2026. Morton brings nearly 40 years of banking experience, including leadership roles at Bank of Montreal and MB Financial. This addition aims to strengthen HBT's leadership as it continues to grow its regional banking operations.
Maze Therapeutics announced positive topline results from its Phase 2 HORIZON trial showing clinical proof-of-concept for MZE829 in APOL1-mediated kidney disease (AMKD). The company plans to advance MZE829 into pivotal trials and start two Phase 2 trials in 2026 for MZE782 targeting phenylketonuria (PKU) and chronic kidney disease (CKD). Maze also …
Maze Therapeutics reported promising topline results from its Phase 2 HORIZON trial of MZE829, an oral dual-mechanism APOL1 inhibitor targeting APOL1-mediated kidney disease. Treatment resulted in a 35.6% mean reduction in proteinuria (uACR) at week 12 across a broad AMKD patient population, with enhanced efficacy in FSGS patients (61.8% reduction)…
Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a significant board restructuring led by majority stockholders Inscobee Inc. and Apimeds Korea, who removed several directors and appointed new ones, including a new CEO. This followed disagreements over a prior merger with MindWave Innovations, with MindWave disputing the board chang…
Picard Medical, parent company of SynCardia Systems, reported revenue growth of 12.5% in 2025 with total revenue of $4.9 million. Despite an operating loss of $13.3 million, the company improved its operating loss and increased cash reserves significantly following successful equity and debt financing. The SynCardia Total Artificial Heart continues…
Tilray Brands, a leading global lifestyle and consumer packaged goods company in cannabis, beverages, and wellness, announced it will release its Q3 fiscal year 2026 financial results before market open on April 1, 2026, followed by a live conference call and webcast.
C4 Therapeutics has dosed the first patient in a Phase 1b trial evaluating the combination of their oral IKZF1/3 degrader cemsidomide with elranatamab (ELREXFIO®), an FDA-approved bispecific antibody, in patients with relapsed or refractory multiple myeloma. The trial aims to establish the optimal dose, assess safety, tolerability, and preliminary …
Lightbridge Corporation (Nasdaq: LTBR) has been selected to serve on the Industry Advisory Board for a $6 million Department of Energy-funded nuclear materials research project at Penn State University. The four-year BTN2M2 consortium aims to advance nuclear materials research using cutting-edge micro- and nano-scale techniques, significantly reduc…
